Several inhibitors (rapamycin analogs) targeting the PI3K/AKT/mTOR pathway have been investigated to counteract the mechanism by which PTEN deletion promotes prostate cancer progression (60), but their antitumor effects have been disappointing. The gene discussed is MTOR; the disease is Familial prostate cancer.